Cardiovascular responses to exogenous platelet-activating factor (PAF) in anesthetized ponies, and the effects of a PAF antagonist, WEB 2086.

This research explores the effects of a substance called platelet-activating factor (PAF) on the cardiovascular system of anesthetized ponies, and tests the efficacy of a PAF antagonist, WEB 2086, in countering these effects.

Introduction to the Experiment

• The research began with the administration of platelet-activating factor (PAF) to anesthetized ponies. PAF is a powerful inflammatory mediator that affects a variety of systems in living organisms.
• It was observed that PAF caused several changes in the cardiovascular system of the ponies, including a decrease in cardiac index leading to systemic hypotension (low blood pressure).
• However, these hypotensive effects were followed by a period of tachycardia (rapid heartbeat), hypertension (high blood pressure), and a return of the cardiac index to its baseline levels.

Additional Research Observations

• Along with the cardiovascular responses, the administration of PAF resulted in increased pulmonary arterial pressure due to pulmonary vasoconstriction, which is the narrowing of the blood vessels in the lungs.
• PAF also caused leukopenia (reduction in white blood cell count) and thrombocytopenia (reduction in blood platelet count), indicating effects on the blood’s cellular components.

Effects of PAF Antagonist WEB 2086

• The research then introduced a specific PAF receptor antagonist known as WEB 2086. Antagonists are substances that can block or diminish the activity of another substance in the body.
• When WEB 2086 was introduced, it blocked all the previously observed changes induced by PAF, showing its effectiveness in countering the effects of PAF.

Effects of the Cyclooxygenase Inhibitor

• Another compound, the cyclooxygenase inhibitor flunixin meglumine, was also utilized in the study.
• It was found to abolish the pulmonary hypertension and tachycardia brought about by PAF and mitigated the systemic hypotension. However, it did not affect the PAF-induced changes in peripheral cellular components.

In Vitro Testing

• In addition to the in-vivo studies with anesthetized ponies, the PAF antagonist was also shown to inhibit platelet aggregation caused by PAF in an in-vitro setting.

Implication of Results

• The changes in the cardiovascular system of the ponies as a result of exogenous PAF administration were found to be similar to those reported after exposure to endotoxins in horses, implying similar underlying mechanisms of action.